Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS Q61K |
| Therapy | Palbociclib + Trametinib |
| Indication/Tumor Type | fibrosarcoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS Q61K | fibrosarcoma | sensitive | Palbociclib + Trametinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment synergistically inhibited proliferation and induced cell cycle arrest of a fibrosarcoma cell line harboring NRAS Q61K in culture and inhibited tumor growth in a cell line xenograft model (PMID: 39148328). | 39148328 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39148328) | Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models. | Full reference... |